Guangzhou’s 15th Five-Year Plan calls for accelerated development of novel
vaccines, antibody therapies, nucleic acid drugs, peptide drugs, blood products
and small-molecule medicines. It directs the development of chemical drugs based on
new targets, new subtypes and new mechanisms, and aims to master manufacturing
technologies for large-volume, clinically urgent and high-end generics. The plan
targets breakthroughs in CRISPR‑Cas gene editing, base editing and cell
reprogramming to speed gene and cell therapy R&D. It prioritizes organ medicine
research—organ development, regeneration, functional regulation and xenogeneic
integration mechanisms—and fast-tracks core hardware and software including
high-precision organ chips, intelligent bioreactors and multimodal
organ-function monitoring and simulation systems. It seeks breakthroughs in
high-performance biocompatible materials, biomimetic matrices and miniaturized
sensors, plus key cross-cutting technologies such as organ-function editing and
reconstruction, cross-scale biomanufacturing processes and organ–mechatronic
decoupling and integrated control algorithms to build a full-chain
design-to-manufacturing-and-regulation technology system.
